Versartis looks to raise $100M in IPO; Caisson expands Novo development pact with $167M deal;

@FierceBiotech: German billionaire pair backs $76M gamble on Glycotope's cancer and fertility drug trials. Article | Follow @FierceBiotech

@JohnCFierce: Purdue preps potential Zohydro killer for FDA review after positive PhIII. News | Follow @JohnCFierce

@DamianFierce: Farewell to dear old Alderley as AstraZeneca finds a buyer for its R&D HQ. Story | Follow @DamianFierce

@EmilyMFierce: FDA approval of Cefaly migraine device is encouraging since triptans used to treat migraines come with risk of rebound headaches. | Follow @EmilyMFierce

> Redwood City, CA-based Versartis has set a range of $16 to $19 a share for its IPO, looking to raise about $81 million. The biotech's lead program is for a long-acting human growth hormone. Story

> Caisson Biotech, which signed on with Novo Nordisk ($NVO) in 2012 for the development of drugs using Caisson's delivery platform HEPtune, expanded the scope of the deal to cover specific indications, including its approach to insulin delivery. Under the revamped agreement, which could bring Caisson up to $167 million in milestone payments, Caisson gives Novo exclusive rights to use the delivery tech for its diabetes products as well as nonexclusive rights to use it for a host of other diseases. Story

> New York-based TG Therapeutics raised $18 million from the sale of 2.7 million shares. It will use the cash to fund development work. Release

> The former CFO of Actelion ($ATLN), Andrew Oakley, has been named CFO at Novimmune. Release

Medical Device News

@FierceMedDev: Would you wear this first-of-its kind migraine prevention device if it worked? Story | Follow @FierceMedDev

@MarkHFierce: This week's FierceDiagnostics has news on Alzheimer's biomarkers, GE and more. Newsletter | Follow @MarkHFierce

@MichaelGFierce: Study: Drug-delivering ring halts HIV, herpes, pregnancy for months at a time. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: PowerVision implanted its fluid intraocular lenses into 10 patients as part of a new clinical study. Article | Follow @EmilyWFierce

@GalenMoore: A cash-strapped SF biotech's ovarian cancer drug may actually get to Phase III. Story | Follow @GalenMoore

> Fresenius Medical Care to pour $140M into Tennessee manufacturing expansion. More

> Myriad can't stop Ambry Genetics from selling its breast cancer test--for now. Story

> J&J's $2.5B-plus metal hip settlement offer approaches April 1 deadline. Article

Pharma News

@FiercePharma: Novartis and Roche now have France eyeing competition issues. Story | Follow @FiercePharma

@TracyStaton: RT from BioPharmaJosh: WSJ looks at how JNJ beat out NVS & CELG for Imbruvica. Article (sub. req.) | Follow @TracyStaton

@EricPFierce: With hemophilia drugs in the pipeline, Bayer Healthcare will invest €500 M in new production in Germany. Release | Follow @EricPFierce

@CarlyHFierce: From FP Marketing: Hearts, stars, diamonds: Pharma could turn pill shapes into lucky charms. More | Follow @CarlyHFierce

> CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients. Piece

> Teva hit with $27.6M settlement in clozapine kickback case. News

Drug Delivery News

> Mallinckrodt's U.S. pain drug approval brings Depomed a $10M delivery tech milestone. More

> NeuroDerm preps for Parkinson's patch PhII trial. Story

> Delivery method uses a cancer cell's power source to trigger drug release. Article

> Study: Drug-delivering ring halts HIV, herpes, pregnancy for months at a time. News

> Caisson expands Novo partnership with $167M insulin-delivery deal. Report

> Nanoparticles breach blood-brain barrier as possible Alzheimer's treatment. Item

Diagnostics News

> 3 Alzheimer's biomarkers build over time but decline after symptoms appear. Story

> Restless legs syndrome mulled as a diagnostic biomarker for multiple conditions. Article

> Boston Heart launches a new inflammation test for cardiovascular disease. Story

> Quest Diagnostics boosts 2014 guidance after closing $570M Solstas acquisition. News

> GE Healthcare prostate cancer imaging agent spurs the formation of a U.K. Dx startup. Story

> Debiopharm invests $6M into Immunexpress for sepsis test development. Brief

Pharma Marketing News

> Big Data's double-edged sword: Better drug marketing, bigger SG&A cost cuts. Story

> GlaxoSmithKline gets judge's say-so for false-advertising suit against Teva. News

> Can rival allergy-drug launches deliver for both Stallergenes and Merck? Story

> Online coupon bank maps a new marketing route into physicians' offices. Story

> Hearts, stars, diamonds: Pharma could turn pill shapes into Lucky Charms. Article

> German med schools perfectly OK with pharma-rep visits and gifts. Brief

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.